USP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis

Similar documents
contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

Revision Bulletin Official April 1, 2014 Alprazolam 1

Should you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Additionally, minor editorial changes have been made to update the monograph to current USP style.

Dissolution Test 2 was validated using an Inertsil ODS-3V brand of L1 column. The typical retention time for donepezil is about 5.5 min.

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

USP 35 Official Monographs / Oxaliplatin 4143 DEFINITION

Ondansetron Hydrochloride Tablets

DOXYCYCLINE HYCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007)

CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

LUMEFANTRINUM LUMEFANTRINE

ANALYTICAL METHOD PROCEDURES

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

Chapter 4: Verification of compendial methods

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)

Egualen Sodium Granules

Change to read: PROCEDURE Buffer: 3.9 g/l of ammonium acetate in water. Adjust

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

Lonicera japonica Flower Dry Extract. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

Lonicera japonica Flower Powder. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

ADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer

USP 35 Official Monographs / Azithromycin 2279 C 38H 72N 2O 12 H 2O

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

EFAVIRENZ Final text for addition to The International Pharmacopoeia

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

Dehydrated Alcohol. » Dehydrated Alcohol contains not less than 99.2 percent, Pharmacopeial Forum Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847

Chapter 5: Identification, Assay and Related Substances

ADVANTAME (TENTATIVE)

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

MEDROXYPROGESTERONE INJECTION

Method Development and Validation Of Prasugrel Tablets By RP- HPLC

This method describes the identification of the following prohibited colorants in cosmetic products:

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Anagrelide HCl in Pharmaceutical Formulation

Volume 6, Issue 2, January February 2011; Article-015

Journal of Drug Delivery and Therapeutics

ASPARTAME. Not less than 98% and not more than 102% on the dried basis. White, odourless, crystalline powder, having a strong sweet taste

Saudi Journal of Medical and Pharmaceutical Sciences

SPECIFICATION & TEST PROCEDURE SODIUM SALICYLATE Technical. Molecular weight : Reference : In-house

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. GB Translated English of Chinese Standard: GB5009.

LC Determination of Deferasirox in Pharmaceutical Formulation

Dissolution study and method validation of alprazolam by high performance liquid chromatography method in pharmaceutical dosage form

King Saud University College of Pharmacy Department of Pharmaceutics. Biopharmaceutics PHT 414. Laboratory Assignments 2010 G 1431 H

INDIGOTINE. Disodium 3,3'-dioxo-[delta 2,2' -biindoline]-5,5'-disulfonate (principal component) (principal component)

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

IDENTIFICATION AND DETERMINATION OF HYDROQUINONE IN COSMETIC PRODUCTS 2 14/11/17 ACM 003 BY TLC AND HPLC

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

Diquat 1,1 -ethylene-2,2 -bipyridium dibromide salt Paraquat 1,1 -dimethyl-4,4 -bipyridium dichloride salt Initial Preparation

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

GB Translated English of Chinese Standard: GB NATIONAL STANDARD OF THE

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

Determination of Carbonyl Compounds In Water by Dinitrophenylhydrazine Derivatization and HPLC/UV*

What actually are dietary supplements? They are consumed in large quantities, but they

Practical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

ASPIRIN (ACETYLSALICYLIC ACID) CERTIFIED REFERENCE MATERIAL

12 Nicarbazin Nicarbazin (4,4 -dinitro carbanilid (DNC) and 2-hydroxy-4,6-dimethyl pyrimidine (HDP))

Fast methods for the determination of ibuprofen in drug products

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

METHOD 8032A ACRYLAMIDE BY GAS CHROMATOGRAPHY

DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR IN-VIVO STUDY OF DICLOFENAC POTASSIUM

FLUDEOXYGLUCOSE ( 18 F) INJECTION: Final text for addition to The International Pharmacopoeia (January 2009)

Appendix II- Bioanalytical Method Development and Validation

A Validated RP-HPLC Method for the Estimation of Procyclidine Hydrochloride in Pharmaceutical Dosage Form

PHENYLEPHRINE HYDROCHLORIDE CERTIFIED REFERENCE MATERIAL

PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES

PYRIPROXYFEN TECHNICAL

Research Article METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ELBASVIR AND GRAZOPREVIR BY RP-HPLC

DISSOLUTION TEST FOR SOLID ORAL DOSAGE FORMS. Proposal for revision for The International Pharmacopoeia. (February 2018)

Impact factor: 3.958/ICV: 4.10 ISSN:

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD TO DETERMINE CINITAPRIDE HYDROGEN TARTARATE IN BULK AND PHARMACEUTICAL FORMULATION

TECHNICAL TEMEPHOS. 1. Specification. Full specification WHO/SIT/19.R4 Revised 10 December Description

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

BRIEFING. (EM2: K. Moore.) RTS C Add the following: Methylcellulose

International Journal of Pharma and Bio Sciences V1(1)2010. HPLC method for analysis of Lercanidipine Hydrochloride in Tablets

H 3 CO H 3 CO S CH 3

International Journal of Pharmaceutical Research & Analysis

TERTIARY BUTYLHYDROQUINONE

CIPAC. CIPAC Free relevant impurities methods:

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

DEVELOPMENT AND VALIDATION OF HPLC METHOD OF DISSOLUTION TEST FOR METOPROLOL SUCCINATE AND CILNIDIPINE

CHAPTER - IV. Acharya Nagarjuna University, Guntur 105

LEAD (Colorimetric) 2. Muffle Furnace: Equipped with pyrometer and capable of operating at controlled temperatures up to 500 C

Development and Validation of a HPLC Method for Determination of Anastrozole in Tablet Dosage Form

SECOBARBITAL Latest Revision: February 15, 1999

Transcription:

. USP 36 Official Monographs / Metformin 4271 System suitability each of 5 s, at about 20,000 rpm, and allow to soak for Sample: System suitability solution 2 min. Repeat these steps two additional times.] Suitability requirements Sample solution: Pass a portion of the Sample stock so- Resolution: NLT 10 between melamine and lution through a suitable filter of 0.45-µm pore size, dismetformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis filtrate to a 200-mL volumetric flask, and dilute with Samples: Sample solution and Diluted sample solution water to volume. Calculate the percentage of any individual impurity in Chromatographic system the portion of the Tablets taken: (See Chromatography 621, System Suitability.) Mode: LC Result = (r U/r S) D 100 Detector: UV 218 nm Column: 3.9-mm 30-cm; 10-µm packing L1 r U = peak response of any individual impurity from Column temperature: 30 the Sample solution Flow rate: 1 ml/min r S = peak response of metformin from the Diluted Injection volume: 10 µl sample solution Run time: Until after the elution locus of metformin re- D = dilution factor for the preparation of the lated compound C Diluted sample solution, 0.001 System suitability Acceptance criteria Sample: System suitability solution Any individual impurity: NMT 0.1% [NOTE The relative retention times for metformin re- Total impurities: NMT 0.6% lated compound B, metformin, and metformin related compound C are 0.86, 1.0, and 2.1 2.3, re- ADDITIONAL REQUIREMENTS spectively. Metformin related compound C can have PACKAGING AND STORAGE: Preserve in tight containers. a variable retention time. The composition of the Mo- Store at controlled room temperature. bile phase may be changed to 1:19, if it elutes at a LABELING: When more than one Dissolution test is given, relative retention time of less than 2.1.] the labeling states the Dissolution test used only if Test 1 Suitability requirements is not used. Resolution: NLT 1.5 between the peaks due to USP REFERENCE STANDARDS 11 metformin related compound B and metformin USP Metformin Hydrochloride RS Tailing factor: NLT 0.8 and NMT 2.0 for the metformin peak Relative standard deviation: NMT 1.5% for the metformin peak and NMT 10% for each of the peaks due to metformin related compound B and Metformin Hydrochloride Extended- metformin related compound C Release Tablets Analysis Samples: Standard solution and Sample solution DEFINITION Calculate the percentage of the labeled amount of Metformin Hydrochloride Extended-Release Tablets contain metformin hydrochloride (C 4H 11N 5 HCl) in the portion NLT 90.0% and NMT 110.0% of the labeled amount of of Tablets taken: metformin hydrochloride (C 4H 11N 5 HCl). Result = (r U/r S) (C S/C U) 100 IDENTIFICATION A. The retention time of the major peak from the Sample r U = peak response from the Sample solution solution corresponds to that from the Standard solution, r S = peak response from the Standard solution as obtained in the Assay. C S = concentration of USP Metformin Hydrochloride RS in the Standard solution ASSAY PROCEDURE C U = nominal concentration of metformin Buffer solution: 0.5 g/l of sodium heptanesulfonate and hydrochloride in the Sample solution 0.5 g/l of sodium chloride in water. Before final dilu- Acceptance criteria: 90.0% 110.0% tion, adjust with 0.06 M phosphoric acid to a ph of 3.85. PERFORMANCE TESTS Mobile phase: Acetonitrile and Buffer solution (1:9). [NOTE To improve the separation, the composition of acetonitrile and Buffer solution may be changed to 1:19, Change to read: if necessary.] Diluent: 1.25% solution of acetonitrile in water DISSOLUTION 711 Standard solution: (L/4000) mg/ml of USP Metformin Test 1 Hydrochloride RS in Diluent, where L is the labeled : ph 6.8 phosphate buffer (6.8 g of monobasic quantity, in mg, of metformin hydrochloride in each potassium phosphate in 1000 ml of water, adjusted Tablet with 0.2 N sodium hydroxide to a ph of 6.8 ± 0.1); System suitability stock solution: 12.5 µg/ml each of 1000 ml USP Metformin Related Compound B RS and USP Metformin Related Compound C RS in Diluent System suitability solution: Dilute 0.5 ml of the System Apparatus 2: 100 rpm for Tablets labeled to contain suitability stock solution with the Standard solution to 500 mg 50 ml. Times: 1, 3, and 10 h Sample stock solution: Finely powder NLT 10 Tablets. Detector: UV 232 nm Transfer powder, equivalent to the average Tablet Standard solution: USP Metformin Hydrochloride RS in weight, to a homogenization vessel, and add 500 ml of a 10% acetonitrile solution. Alternately, homogenize and allow to soak until the sample is fully homogenof 0.45-µm pore size. Dilute, if necessary, with test through a suitable hydrophilic polyethylene filter ized. [NOTE A suggested homogenization sequence is as follows. Homogenize the sample using five pulses,

4272 Metformin / Official Monographs USP 36 to a concentration similar to that of the Standard C 2 = content of metformin hydrochloride in solution. at the second time interval Analysis: Calculate the percentage of the labeled V = volume of, 1000 ml amount of metformin hydrochloride (C 4H 11N 5 HCl) re- SV 1 = volume of the sample withdrawn at 1 h (ml) leased at each time point: C 1 = content of metformin hydrochloride in at 1 h Result = [(A U/A S) C S (V V S) + (C 60 V S) + (C 180 V S) 100]/L Percentage dissolved at the nth time point: A U = absorbance of the Sample solution Result = {C n [V (n 1)V S] + (C 1 + C 2 + + C n 1) V S A S C S = absorbance of the Standard solution = concentration of the Standard solution 100}/L C n = content of metformin hydrochloride in V = initial volume of in the vessel (ml) at the nth time interval V S = volume withdrawn from the vessel for V = volume of, 1000 ml previous samplings (ml) n = time interval of interest C 60 = concentration of metformin hydrochloride in V S = volume of sample withdrawn at each time determined at 1 h interval (ml) C 180 = concentration of metformin hydrochloride in C = as C 1, C 2, C 3, C n 1, the content of determined at 3 h metformin hydrochloride in at each time interval Tolerances: See Table 1. Tolerances: See Table 2. Table 1 Time Amount Dissolved, Amount Dissolved, Table 2 (h) 500-mg Tablet 750-mg Tablet Time Amount 1 20% 40% 22% 42% (h) Dissolved 3 45% 65% 49% 69% 1 20% 40% 10 NLT 85% NLT 85% 2 35% 55% 6 65% 85% 10 NLT 85% specified conform to Acceptance Table 2 in Dissolution Test 2: If the product complies with this test, the label- specified conform to Acceptance Table 2 in Dissolution ing indicates that it meets USP Dissolution Test 2. : Prepare as directed for Test 1; 1000 ml. Test 3: If the product complies with this test, the label- Apparatus 2: 100 rpm ing indicates that it meets USP Dissolution Test 3. Times: 1, 2, 6, and 10 h, Apparatus 1, Apparatus 2, and Analy- Detector: UV 232 nm sis: Proceed as directed in Test 1. Standard solution: USP Metformin Hydrochloride RS in Times: 1, 2, 5, and 12 h for Tablets labeled to contain 500 mg; and 1, 3, and 10 h for Tablets labeled to contain test through a suitable polyethylene filter of 0.45-µm Detector: UV 232 nm pore size. Dilute, if necessary, with to a con- Standard solution: USP Metformin Hydrochloride RS in centration that is similar to that of the Standard solution. Analysis: Calculate, in mg/ml, the content of test through a suitable hydrophilic polyethylene filter metformin hydrochloride (C 4H 11N 5 HCl), C t, in Me- of 0.45-µm pore size. Dilute, if necessary, with dium at each time point, t: to a concentration similar to that of the Standard Result = (A U C S D U)/A S solution. Analysis: Calculate the percentage of the labeled amount of metformin hydrochloride (C 4H 11N 5 HCl) re- A U = absorbance of the Sample solution leased at each time point: C S = concentration of metformin hydrochloride in the Standard solution Result = {[(A U/A S) C S (V V S) + (C 60 V S) + (C 120 D U = dilution factor of the solution under test V S) + (C 300 V S) + (C 720 V S)] 100}/L Calculate the percentage of the labeled amount of A U = absorbance of the Sample solution metformin hydrochloride (C 4H 11N 5 HCl) dissolved at each time point by the following formulas. Percentage dissolved at the first time point (1 h): Result = (C 1 V 100)/L V V S = initial volume of in the vessel (ml) = volume withdrawn from the vessel for previous samplings (ml) C 1 = content of metformin hydrochloride in C 60 = concentration of metformin hydrochloride in at the first time interval determined at 1 h V = volume of, 1000 ml C 120 = concentration of metformin hydrochloride in determined at 2 h Percentage dissolved at the second time point (2 h): C 300 = concentration of metformin hydrochloride in Result = [C determined at 5 h 2 (V SV 1) + C 1 SV 1 100]/L C 720 = concentration of metformin hydrochloride in determined at 12 h

USP 36 Official Monographs / Metformin 4273 Tolerances: See Tables 3 and 4. sample holder, making sure that the Tablets are vertical at the bottom of the baskets. Table 3. For Tablets Labeled to Contain 500 mg Calculate, in mg/ml, the content of metformin hydrochloride (C 4H 11N 5 HCl), C t, in at each time Time Amount point, t, by the formulas specified in Test 2. (h) Dissolved Tolerances: See Table 6. 1 20% 40% 2 35% 55% Table 6 5 60% 80% Time Amount Dissolved, Amount Dissolved, 12 NLT 85% (h) 500-mg Tablet 1000-mg Tablet 2 NMT 30% NMT 30% 8 60% 85% 65% 90% Table 4. For Tablets Labeled to Contain 16 NLT 90% NLT 90% Time Amount (h) Dissolved 1 22% 42% 3 49% 69% specified conform to Acceptance Table 2 in Dissolution 10 NLT 85% Test 6: If the product complies with this test, the label- ing indicates that it meets USP Dissolution Test 6. : ph 6.8 phosphate buffer (6.8 g of monobasic specified conform to Acceptance Table 2 in Dissolution potassium phosphate in 1000 ml of water, adjusted with 0.2 N sodium hydroxide to a ph of 6.8 ± 0.05); Test 4: If the product complies with this test, the label- 1000 ml, deaerated ing indicates that it meets USP Dissolution Test 4. Apparatus 2: 100 rpm, with USP sinker, if necessary : Prepare as directed for Test 1; 1000 ml. Detector: UV 233 nm Apparatus 2: 100 rpm Standard solution: USP Metformin Hydrochloride RS in Times: 1, 3, 6, and 10 h Detector: UV 250 nm (shoulder) Standard solution: USP Metformin Hydrochloride RS in test through a suitable hydrophilic polyethylene filter of 0.45-µm pore size. Dilute, if necessary, with to a concentration similar to that of the Standard test through a suitable filter of 0.45-µm pore size. Di- solution. lute, if necessary, with to a concentration sim- Analysis: Calculate the percentage of the labeled ilar to that of the Standard solution. amount of metformin hydrochloride (C 4H 11N 5 HCl) re- Analysis: Calculate, in mg/ml, the content of leased at each time point: metformin hydrochloride (C 4H 11N 5 HCl), C t, in at each time point, t, by the formulas specified in Result = {[(A U/A S) C S (V V S) + (C 60 V S) + (C 180 Test 2. V S) + (C 600 V S)] 100}/L Tolerances: See Table 5. A U = absorbance of the Sample solution Table 5 Time Amount (h) Dissolved V = initial volume of in the vessel (ml) 1 20% 40% V S = volume withdrawn from the vessel for 3 45% 65% previous samplings (ml) 6 65% 85% C 60 = concentration of metformin hydrochloride in 10 NLT 85% determined at 1 h C 180 = concentration of metformin hydrochloride in determined at 3 h C 600 = concentration of metformin hydrochloride in specified conform to Acceptance Table 2 in Dissolution determined at 10 h Test 5: If the product complies with this test, the labeling Tolerances: See Table 7. indicates that it meets USP Dissolution Test 5. : ph 6.8 phosphate buffer (6.8 g of monobasic Table 7 potassium phosphate in 1000 ml of water, adjusted with 0.2 N sodium hydroxide to a ph of 6.8 ± 0.1); Time Amount Dissolved, Amount Dissolved, 900 ml, deaerated (h) 500-mg Tablet 750-mg Tablet Apparatus 1: 100 rpm, with the vertical holder described 1 20% 40% 20% 40% in Figure 1 and Figure 2 3 45% 65% 45% 65% Times: 2, 8, and 16 h Detector: UV 250 nm 10 NLT 85% NLT 85% Standard solution: USP Metformin Hydrochloride RS in test through a suitable filter of 0.45-µm pore size. Dispecified conform to Acceptance Table 2 in Dissolution lute, if necessary, with to a concentration similar to that of the Standard solution. Analysis: Place a vertical sample holder into each basing indicates that it meets USP Dissolution Test Test 7: If the product complies with this test, the labelket (see Figures 1 and 2). Place 1 Tablet inside the 7.

4274 Metformin / Official Monographs USP 36 Figure 1 : Prepare as directed in Test 1; 1000 ml. Analysis: Calculate the percentage of the labeled amount of metformin hydrochloride (C 4H 11N 5 HCl) re- leased at each time point: Apparatus 2: 50 rpm, with USP sinker, for Tablets labeled to contain 500 mg Result = {[(A U/A S) C S (V V S) + (C 60 V S) + (C 180 Times: 1, 3, and 10 h V S) + (C 600 V S)] 100}/L Detector: UV 232 nm Standard solution: USP Metformin Hydrochloride RS in A U = absorbance of the Sample solution test through a suitable filter of 0.45-µm pore size. Di- lute, if necessary, with to a concentration sim- V = initial volume of in the vessel (ml) ilar to that of the Standard solution. V S = volume withdrawn from the vessel for previous samplings (ml) C 60 = concentration of metformin hydrochloride in determined at 1 h

USP 36 Official Monographs / Metformin 4275 C 180 = concentration of metformin hydrochloride in specified conform to Acceptance Table 2 in Dissolution determined at 3 h C 600 = concentration of metformin hydrochloride in Test 8: If the product complies with this test, the label- determined at 10 h ing indicates that it meets USP Dissolution Test 8. : Prepare as directed in Test 1; 1000 ml. Tolerances: See Table 8. Table 8 Apparatus 2: 100 rpm, with sinker, for Tablets labeled to contain 500 mg Time Amount Dissolved, Amount Dissolved, Times: 1, 2, 6, and 10 h (h) 500-mg Tablet 750-mg Tablet Detector: UV 232 nm 1 20% 40% 20% 40% Standard solution: USP Metformin Hydrochloride RS in 3 45% 65% 40% 60% 10 NLT 85% NLT 80% test through a suitable filter of 0.45-µm pore size. Dilute, if necessary, with to a concentration sim- ilar to that of the Standard solution. Figure 2

4276 Metformin / Official Monographs USP 36 Analysis: Calculate the percentage of the labeled C 3 = concentration of metformin hydrochloride in amount of metformin hydrochloride (C 4H 11N 5 HCl) re- determined at the third time point leased at each time point: C 4 = concentration of metformin hydrochloride in Result = {[(A U/A S) C S (V V S) + (C 60 V S) + (C 120 determined at the fourth time point V S) + (C 360 V S) + (C 600 V S)] 100}/L A U = absorbance of the Sample solution Tolerances: See Tables 10 and 11. Table 10. For Tablets Labeled to Contain 500 mg V = initial volume of in the vessel (ml) Time Amount V S = volume withdrawn from the vessel for (h) Dissolved previous samplings (ml) 1 20% 40% C 60 = concentration of metformin hydrochloride in 5 45% 65% determined at 1 h 12 70% 90% C 120 = concentration of metformin hydrochloride in determined at 2 h 20 NLT 85% C 360 = concentration of metformin hydrochloride in determined at 6 h C 600 = concentration of metformin hydrochloride in Table 11. For Tablets Labeled to Contain determined at 10 h Time Amount (h) Dissolved Tolerances: See Table 9. 1 20% 45% 4 45% 70% Table 9 10 70% 95% Time Amount Dissolved, Amount Dissolved, 24 NLT 85% (h) 500-mg Tablet 750-mg Tablet 1 20% 40% 20% 40% 2 30% 50% 35% 55% specified conform to Acceptance Table 2 in Dissolution 6 65% 85% 75% 95% 10 NLT 85% NLT 85% Test 10: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 10. hydrochloride (C : 0.05 M phosphate buffer (prepared by dis- 4H 11N 5 HCl) dissolved at the times specified conform to Acceptance Table 2 in Dissolution solving 6.8 g of potassium dihydrogen phosphate in 250 ml of water, adding 77 ml of 0.2 N sodium hy- Test 9: If the product complies with this test, the labeldium hydroxide or 2 N hydrochloric acid to a ph 6.8, droxide and 500 ml of water, adjusting with 2 N soing indicates that it meets USP Dissolution Test 9. : 0.05 M phosphate buffer, ph 6.8; 1000 ml and diluting with water to 1000 ml), ph 6.8; 1000 ml Apparatus 1: 100 rpm, for Tablets labeled to contain Apparatus 2: 100 rpm, for Tablets labeled to contain Apparatus 2: 100 rpm for Tablets labeled to contain 500 mg 500 mg Times: 1, 5, 12, and 20 h for Tablets labeled to contain Times: 1, 3, and 10 h 500 mg; and 1, 4, 10, and 24 h for Tablets labeled to Standard solution: (L/100,000) mg/ml of USP contain Metformin Hydrochloride RS in, where L is the Standard solution: 0.5 mg/ml of USP Metformin Hyh at room temperature. label claim, in mg/tablet. This solution is stable for 72 drochloride RS in Sample solution: At the times specified, withdraw test through a suitable filter of 0.45-µm pore size. 10 ml of the solution under test and replace with Detector: UV 232 nm 10 ml of previously equilibrated at 37.0 ± Path length: 0.01 cm, flow cell 0.5. Centrifuge at 2500 rpm for 10 min. Dilute a por- Blank: tion of the supernatant with to obtain a theo- Analysis: Calculate the percentage of the labeled retical concentration of (L/100,000) mg/ml, where L is amount of metformin hydrochloride (C the label claim, in mg/tablet. 4H 11N 5 HCl) released at each time point: Detector: UV 233 nm Path length: 1 cm Result = {[(A U/A S) C S (V V S) + (C 1 V S) + (C 2 V S) Blank: + (C 3 V S) + (C 4 V S)] 100}/L Analysis: Calculate the concentration of metformin hydrochloride (C i) at each time point: A U = absorbance of the Sample solution AS = absorbance of the Standard solution C i = (A U/A S) C S A U = absorbance of the Sample solution V = initial volume of in the vessel (ml) V S = volume withdrawn from the vessel for previous samplings (ml) C Calculate the cumulative percentage of the labeled 1 = concentration of metformin hydrochloride in determined at the first time point amount of metformin hydrochloride (C 4H 11N 5 HCl) dissolved (Q i) at each time point (i): C At i = 1: 2 = concentration of metformin hydrochloride in determined at the second time point Q 1 = (C 1 V/L) 100

USP 36 Official Monographs / Metformin 4277 At i = 3: Tolerances: See Table 13. Q 3 = [C 3(V V S) + (C 1 V S)] 100/L Table 13 At i = 10: Time Amount (h) Dissolved Q 10 = [C 10(V 2V S) + (C 1 + C 3)V S] 100/L 1 25% 45% 3 50% 70% V = initial volume of, 1000 ml V S = sampling volume, 10 ml 10 NLT 80% Tolerances: See Table 12. specified conform to Acceptance Table 2 in Dissolution Table 12 Time Amount Test 12: If the product complies with this test, the la- (h) Dissolved beling indicates that it meets USP Dissolution Test 12. 1 25% 45% : ph 6.8 phosphate buffer (prepared as directed in Test 1); 1000 ml 3 50% 70% Apparatus 1: 100 rpm 10 NLT 85% Times: 1, 4, and 12 h Standard stock solution: 0.2 mg/ml of USP Metformin Hydrochloride RS in Standard solution: 0.01 mg/ml of USP Metformin Hyspecified conform to Acceptance Table 2 in Dissolution drochloride RS in water, from the Standard stock solution Test 11: If the product complies with this test, the label- Sample solution: At the times specified, withdraw ing indicates that it meets USP Dissolution Test 11. 10 ml of the solution under test, and replace with : ph 6.8 phosphate buffer; 1000 ml 10 ml of previously equilibrated at 37.0 ± 0.5. Pass it through a suitable filter, discarding the first few ml of the filtrate. Apparatus 2: 100 rpm for Tablets labeled to contain For Tablets labeled to contain 500 mg: Dilute 500 mg 2.0 ml of the filtrate with water to 100 ml. Times: 1, 3, and 10 h For Tablets labeled to contain 1000 mg: Dilute Standard solution: 7.5 µg/ml of USP Metformin Hy- 1.0 ml of the filtrate with water to 100 ml. drochloride RS in Detector: UV 232 nm Sample solution: At the times specified, withdraw Blank: Dilute 1 ml of with water to 100 ml. 10 ml of the solution under test, and pass it through a Analysis: Calculate the concentration, C i, in mg/ml of suitable filter of 0.45-µm pore size, discarding the first metformin hydrochloride (C 4H 11N 5 HCl) in the sample 3 ml of filtrate. Dilute 3.0 ml of the filtrate with Mewithdrawn at each time point (i): dium to 200 ml. For Tablets labeled to contain, dilute 2.0 ml of the filtrate with to Result i = (A U/A S) C S D 200 ml. Replace the volume of taken with the same volume of preheated at 37.0 ± 0.5. A U = absorbance of the Sample solution Detector: UV 232 nm Path length: 1 cm Blank: Calculate the percentage of the labeled amount of D = dilution factor of the Sample solution metformin hydrochloride (C 4H 11N 5 HCl) dissolved at Calculate the percentage of the labeled amount of each time point: metformin hydrochloride (C 4H 11N 5 HCl) dissolved (Q i) at each time point (i): Q i = (A U/A S) (C S/L) V D 100 Result 1 = C 1 V (1/L) 100 At 1 h: Result = Q 1 Result 2 = {[C 2 V] + [C 1 V S]} (1/L) 100 At 3 h: Result = Q 3 + [(Q 1 10)/V] Result 3 = {[C 3 V] + [(C 2 + C 1) V S]} (1/L) 100 At 10 h: C i = concentration of metformin hydrochloride in the portion of sample withdrawn at time Result = Q 10 + {[(Q 1 10)/V] + [(Q 3 10)/V]} V point i = initial volume of, 1000 ml A U = absorbance of the Sample solution V S = volume of the Sample solution withdrawn, 10 ml Tolerances: See Table 14. L V = label claim (mg/tablet) = volume of, 1000 ml Table 14 D = dilution factor of the Sample solution Time point Time Amount (i) (h) Dissolved 1 1 NMT 15% 2 4 35% 65% 3 12 NLT 85%

.. 4278 Metformin / Official Monographs USP 36 Heavy metals, Method II 231 : 0.002%. Assay Transfer to a conical flask about 400 mg of specified conform to Acceptance Table 2 in Dissolution Methacholine Chloride, previously dried and accurately (RB 1-Jul-2012) weighed (because it is very hygroscopic, store the dried ma- UNIFORMITY OF DOSAGE UNITS 905 : Meet the terial in a vacuum desiccator), dissolve it in 50 ml of glacial requirements acetic acid, add 10 ml of mercuric acetate TS and 1 drop of crystal violet TS, and titrate with 0.1 N perchloric acid VS to IMPURITIES a blue-green endpoint. Perform a blank determination, and ORGANIC IMPURITIES make any necessary correction. Each ml of 0.1 N perchloric Mobile phase, Sample solution, and Chromatographic acid is equivalent to 19.57 mg of C system: Proceed as directed in the Assay. 8H 18ClNO 2. Analysis: From the chromatogram of the Sample solution obtained in the Assay, calculate the percentage of each impurity in the portion of Tablets taken: Result = (r U/r T) 100 Methacycline Hydrochloride r U = peak response for each impurity r T = sum of all the peak responses Acceptance criteria Individual impurities: NMT 0.1% Total impurities: NMT 0.6% [NOTE Disregard any peak less than 0.05%, and disregard any peak observed in the blank.] C 22H 22N 2O 8 HCl 478.88 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a, ADDITIONAL REQUIREMENTS 6,11,lum12a-octahydro-3,5,10,12,12a-pentahydroxy- PACKAGING AND STORAGE: Preserve in well-closed, light- 6-methylene-1,11-dioxo-, monohydrochloride, [4S-(4α, resistant containers, and store at controlled room 4aα,5α,5aα,12aα)]-. temperature. 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5, LABELING: When more than one dissolution test is given, 10,12,12a-pentahydroxy-6-methylene-1,11-dioxothe labeling states the Dissolution test used only if Test 1 2-naphthacenecarboxamide monohydrochloride is not used. [3963-95-9]. USP REFERENCE STANDARDS 11 USP Metformin Hydrochloride RS» Methacycline Hydrochloride has a potency USP Metformin Related Compound B RS equivalent to not less than 832 µg and not more 1-Methylbiguanide hydrochloride. than 970 µg of methacycline (C 22 H 22 N 2 O 8 ) per C 3H 9N 5HCl 151.60 USP Metformin Related Compound C RS mg. N,N-Dimethyl-[1,3,5]triazine-2,4,6-triamine. Packaging and storage Preserve in tight, light-resistant C 5H 10N 6 154.17 containers. USP Reference standards 11 USP Doxycycline Hyclate RS USP Methacycline Hydrochloride RS Identification, Ultraviolet Absorption 197U Methacholine Chloride Solution: 20 µg per ml. : hydrochloric acid in methanol (1 in 1200). Absorptivity at 345 nm, calculated on the dried basis, is between 88.4% and 96.4% of the USP Methacycline Hydrochloride RS, the potency of the Reference Standard being C 8H 18ClNO 2 195.69 taken into account. 1-Propanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride, (±)-. Crystallinity 695 : meets the requirements. (±)-(2-Hydroxypropyl)trimethylammonium chloride ph 791 : between 2.0 and 3.0, in a solution containing acetate [62-51-1]. 10 mg of methacycline per ml. Water, Method I 921 : not more than 2.0%.» Methacholine Chloride, dried at 105 for Assay 4 hours, contains not less than 98.0 percent and Mobile phase Prepare a mixture of 0.2 M ammonium not more than 101.0 percent of C 8 H 18 ClNO 2. Packaging and storage Preserve in tight containers. Identification A: Infrared Absorption 197M. B: A solution (1 in 50) responds to the tests for Chloride 191. Loss on drying 731 Dry it at 105 for 4 hours: it loses not more than 1.5% of its weight. Residue on ignition 281 : not more than 0.1%. Acetylcholine chloride To 2 ml of a solution (1 in 10) add 3 ml of a solution of sodium perchlorate (1 in 5), shake, and immerse in ice water for 5 minutes: no precipitate is formed. oxalate, dimethylformamide, and 0.1 M edetate disodium (11:5:4), adjust with tetrabutylammonium hydroxide, 40 percent in water, to a ph of 7.0, and filter. Make adjustments, if necessary (see System Suitability under Chromatography 621 ). System suitability preparation Prepare a solution of USP Methacycline Hydrochloride RS and USP Doxycycline Hyclate RS in Mobile phase containing about 0.5 mg of each per ml. Standard preparation Quantitatively dissolve an accurately weighed quantity of USP Methacycline Hydrochloride RS in Mobile phase to obtain a solution having a known concentration of about 0.5 mg per ml. Assay preparation Transfer about 50 mg of Methacycline Hydrochloride, accurately weighed, to a 100-mL volumetric flask, dilute with Mobile phase to volume, and mix.